Feline mammary tumours: a literature review by Antunes, Sandra Cristina da Silva
 ESCOLA UNIVERSITÁRIA VASCO DA GAMA 
 
MASTER’S DEGREE 
 
 
 
FELINE MAMMARY TUMOURS: A LITERATURE REVIEW 
 
 
 
 
 
 
Sandra Cristina da Silva Antunes 
 
 
Coimbra, July 2014 
 ESCOLA UNIVERSITÁRIA VASCO DA GAMA 
 
MASTER’S DEGREE 
 
 
 
FELINE MAMMARY TUMOURS: A LITERATURE REVIEW 
Coimbra, July 2014 
 
 
Author 
Sandra Cristina da Silva Antunes 
 
Supervisors 
Professor Anália do Carmo 
(Escola Universitária Vasco da Gama) 
Dr. Hugo Vilhena 
(Escola Universitária Vasco da Gama) 
(Hospital Veterinário do Baixo Vouga) 
 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Thesis to obtain the Master Degree in Veterinary Medicine in Escola Universitária Vasco da Gama” 
 
 
ii 
 
ABSTRACT 
 
Mammary tumours (MTs) are among the most common tumours in the cat, 17% of the tumours among 
female cats. These tumours are highly infiltrative tumours, frequently associated to lymph node 
metastasis at the time of the initial diagnosis and have a mean survival rate from the time of diagnosis 
between 6 to 12 months. The aetiology of MTs is not clearly understood but some risk factors have been 
pointed, namely, age, breed, reproductive status and exposure to oestrogen and progesterone. 
In order to establish an adequate treatment it is important to obtain the histological classification, the 
grading and the staging of the tumour, since most of the MTs present local and distant metastasis at the 
time of the diagnosis. Tumours of the feline mammary gland are histologically classified according to 
the diagnostic criteria proposed by the World Health Organization (WHO). This classification is based 
on descriptive morphology and divides MTs into four main groups: mammary hyperplasia/dysplasia; 
benign tumours, malignant tumours, and unclassified tumours. The histological grade is determined 
according to an adaptation of the classification used by Elston and Ellis and is based on the degree of 
tubule formation, degree of nuclear and cellular pleomorphism, and mitotic count. The staging of feline 
MT is based on a modified WHO clinical staging system. 
Surgery is the most widely used treatment for mammary tumours in the cat; it is used alone or in 
combination with chemotherapy. Radical mastectomy is the surgical method of choice because it 
significantly reduces the chance of local tumour recurrence. The inguinal lymph node is virtually always 
removed with the mammary gland, while the axillary lymph nodes are removed only if enlarged and 
cytological positive for neoplastic cells. 
Combination chemotherapy using doxorubicin and cyclophosphamide has been shown to induce short-
term responses in about half of the cats with metastatic or nonresectable local disease, and is 
recommended after complete excision of the tumour to prolong disease-free period. However, 
controversial results due to the effect of the adjuvant therapy have been reported and therefore further 
studies are needed to better understand the role of doxorubicin and cyclophosphamide as adjuvant 
therapy. 
The most significant prognostic factors affecting recurrence and survival times for cats with malignant 
mammary tumours are tumour size, extent of surgery, and histologic grading. Tumour size been 
considered the most important prognostic factor. Recently, efforts have been made to determine 
molecular markers in order to determine their role as prognostic factor or therapeutic targets but until 
the moment there are no consistent results.  
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RESUMO 
 
Os tumores mamários (TMs) estão entre os tumores mais comuns no gato, representando 17% 
dos tumores nas gatas. Estes tumores são altamente infiltrativos, apresentando frequentemente 
metástases no momento do diagnóstico, apresentando uma taxa média de sobrevivência a partir do 
momento do diagnóstico, que varia entre 6 a 12 meses. A etiologia dos TMs não é claramente 
compreendida, mas alguns fatores de risco têm sido apontados, tais como a idade, a raça, o estado 
reprodutivo e a exposição aos estrogénios e progesterona. 
A fim de estabelecer um tratamento adequado é importante obter a classificação histológica, o 
grau histológico e o estadiamento do tumor, pois a maioria dos TMs apresenta metástases locais e 
distantes, no momento do diagnóstico. Os tumores da glândula mamária felina são histologicamente 
classificados, de acordo com os critérios de diagnóstico, propostos pela Organização Mundial da Saúde 
(OMS). Esta classificação é baseada em características morfológicas, encontrando-se os TMs 
organizados em quatro grupos principais: hiperplasia mamária / displasia, tumores benignos, tumores 
malignos e tumores não classificados. O grau histológico é determinado de acordo com uma adaptação 
da classificação utilizada por Elston e Ellis e baseia-se na formação de túbulos, grau de pleomorfismo 
nuclear e celular, e na atividade mitótica. O estadiamento dos TMs felinos baseia-se no sistema de 
estadiamento clínico da OMS modificado. 
A cirurgia é o tratamento mais utilizado para as neoplasias mamárias no gato; pode ser 
efetuada de forma isolada ou em combinação com quimioterapia. A mastectomia radical é o método 
cirúrgico de escolha, pois reduz significativamente a recorrência local do tumor. Os gânglios linfáticos 
inguinais são quase sempre removidos com a glândula mamária, enquanto que, os linfonodos axilares 
são removidos somente quando apresentam tamanho aumentado e células neoplásicas na citologia. 
A quimioterapia com doxorrubicina e ciclofosfamida como terapia adjuvante, após a excisão 
completa do tumor é recomendada para prolongar o período livre de doença. No entanto, os resultados 
obtidos com a quimioterapia adjuvante têm sido controversos, sendo necessários mais estudos para 
entender melhor o papel de doxorrubicina e da ciclofosfamida como terapia adjuvante. 
Os fatores prognósticos mais importantes que afetam a recorrência e sobrevivência dos gatos 
com tumores mamários malignos são o tamanho do tumor, a extensão da cirurgia e a classificação 
histológica. O tamanho do tumor é o fator de prognóstico mais importante. Recentemente, têm sido 
efetuados esforços para determinar novos marcadores moleculares a fim de determinar o seu papel 
como fator prognóstico ou como alvos terapêuticos, mas até ao momento não há resultados 
consistentes. 
 
Palavras-chave: Tumores mamários; Gatas; Grau histológico; Estadiamento; Fatores de prognóstico. 
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1. INTRODUCTION 
 
The mammary tumours (MTs) are a very important cause of morbidity among cats.1 In a study performed 
in the United States of America these tumours were considered the third most diagnosed tumours after 
skin tumours and hematopoietic neoplasms.2,3 However, in a study performed, in Brazil, by Togni et al. 
(2013) MTs were the second most diagnosed, after skin tumours and before the hematopoietic 
neoplasm.4 These discrepancies among the prevalence of feline MT are due to differences in the 
inclusion criteria, tumour diagnosis and classification.2,3,4,5,6 
The MTs represent 17% of tumours affecting female cats, being less frequent in males ( 1 to 5%) 7,8,9,10 
and at least 85% to 95% of feline MTs are malignant.2,11 Histologically, most malignant MT 
are adenocarcinomas, being the tubular and papillary types more common than the solid or mucoid 
types.12,13 Feline mammary carcinoma are highly infiltrative tumours, frequently associated with lymph 
node metastases at the time of the initial diagnosis and have a mean survival rate from the time of 
diagnosis that ranges between 6 to 12 months.14,15 Fibroadenomatous hyperplasia (fibroepithelial 
hypertrophy, feline mammary hypertrophy) is the most common histopathologic lesions in cats.15 It is a 
consequence of an exaggerated proliferative response of mammary glandular tissue to several 
situations, namely pregnant or pseudopregnant queens, cats receiving prolonged megestrol acetate or 
medroxyprogesterone acetate therapy, cats receiving progestational compound when endogenous 
levels of oestrogen are increased.16 
The aetiology of MTs remains poorly understood, however some factors have been pointed as risk 
factors for MTs namely age, breed, reproductive status and exposure to oestrogen and progesterone.15 
In fact, MTs are more frequent in middle-aged to older cats, with the mean age of diagnosis between 
10-12 years.8,17,18,19 The risk increases with age, presenting a peak between 7 to 9 years and continuing 
to increase until 12 to 14 years.17  
The Domestic Shorthair cat is the breed more frequently affected.2,8,18 Nevertheless, when MTs are 
diagnosed at younger age, Siamese cats and other Oriental breeds are the most affected.7,8 Since 
genetic predisposition for a disease is often associated with a younger age of diagnosis,15 and young 
Siamese cats have an increased risk for many types of tumour, it is possible that Siamese cats present 
breed-associated germ line alterations that confer increase risk for many different malignancies.15 
Relatively to reproductive and hormonal status, it is considered that oestrogen and progesterone play 
an important role in mammary tumorigenesis, and also that exposure to these hormones at an early age 
seems to be crucial for MTs development.15,20 In fact, some studies revealed that queens spayed before 
1 year of age have a decreased risk of developing MTs and that sexually intact queens have a sevenfold 
higher risk of feline mammary carcinoma than spayed cats.8,11,17,20 Consistently with these results, other 
studies indicated that ovarihysterectomy (OHE) may be protective against MTs development.2,20 
Nevertheless, according to Overley et al. (2005), the protective effect of OHE diminishes quickly over 
the first years; risk reductions of 91%, 86%, and 11% were achieved in cats that were 
ovariohysterectomized before 6 months, between 7 and 12 months, or between 13 and 24 months, 
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respectively, and no benefit was found after 24 months.20  According to the same study, cats spayed 
after 2 years of age had a statistically significant increased risk to develop MTs compared with intact 
cats, and also that a gradual loss of protection occurred with increasing hormone exposure prior to 
OHE.20 In addition to endogenous ovarian hormonal influence, the long-term exposure to exogenous 
progestins or to oestrogen-progestin to prevent pregnancy or control of aggressive behaviour, increases 
the risk of both benign and malignant MTs development, while intermittent or occasional progestin 
administration has no effect.8,15 According to several studies, these effects were associated to the fact 
that a prolonged steroid exposure induces proliferation of mammary epithelial cells and facilitates the 
accumulation of genetic errors, contributing to the development of MTs.11,20  
As already mentioned, MTs are rare in males, but in a report of 22 cases, 8 (36%) had a history of 
progestin administration.9 In other study, performed by Jacobs et al. (2010), cats with repeatedly 
injections of medroxyprogesterone acetate for inter-cat aggression and urinary house soiling, also 
demonstrated development of mammary adenocarcinoma.21 
Obesity and an unbalanced diet have been linked to increased risk of tumours of the mammary gland.22 
Nunes et al. (2011) found that sixteen cats (66,7%) with neoplasia were fed by a mixed diet (homemade 
food and feed industrialized), while five cats (20,8%) received only animal feed industries, and only 
three cats (12,5%) ate homemade diet.22 An unbalanced diet with high caloric levels could predisposed 
to an occurrence of MTs analysed in cats but the correlation between diet and MTs needs to be 
clarified.22 
Other breeding-related factors such as age at first pregnancy, number of pregnancies, 
pseudopregnancy and changes in the oestrous cycle were suggested as risk factors, but there is no 
consensus regarding their contribution for the development of MTs.20  
Taking in consideration that MTs are very aggressive tumours, their aetiology and prognosis is poorly 
understood, it seems important to perform a bibliographic revision in order to clarify some of the 
discrepancies.  
 
2. CLINICAL PRESENTATION AND DIAGNOSIS OF FELINE MAMMARY TUMOURS 
 
Cats have four pairs of mammary glands, two thoracic pairs (T1; T2) and two abdominal pairs (A1; A2), 
(Figure 1) and in some cats additional glands may be present at the inguinal region.16,23 The secretory 
unit of the mammary gland is the alveolus, which is constituted by an inner layer of cuboidal secretory 
epithelial cells and an outer layer of myoepithelial cells. In the stroma of the alveoli, there are plasma 
cells that secrete immunoglobulin A.16,23 Secretory alveoli drain into collecting alveoli, which drain into 
intralobular ducts, then into interlobular ducts that continue into lobar lactiferous ducts, and finally open 
into lactiferous sinus. The lactiferous sinus is continuous with the teat sinus.16,23 The arterial supply to 
the thoracic glands is provided by the lateral thoracic vessels, the intercostal and the internal thoracic 
vessels.16,23 The arterial supply of the abdominal glands occurs through cranial superficial epigastric 
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artery.16,23 The venous drainage occurs through vessels similar to the arteries and also through small 
veins that cross midline and establish communication between contralateral glands.16,23 Regarding 
lymph drainage it is generally considered that mammary glands drain cranially towards the axillary lymph 
center and caudally towards superficial inguinal lymph center.16,23 Malignant MTs may occur in any 
gland, but are more frequent in the abdominal glands.16 Due to its aggressivity MTs may spread to other 
glands, to ipsilateral regional lymph nodes and also to other organs.8,15,16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The development of malignant MTs is usually characterized by a nodular mass in one or more mammary 
glands. Cats tend to lick and groom the area excessively, and a strong odour can result as the tumour 
becomes ulcerated, necrotic and infected. General signs of illness such as anorexia or depression are 
often seen as the disease progresses.16,24  
A detailed history should be collected, giving particular attention to breed, age, reproduction status, age 
at ovariohysterectomy and the use of progestins or oestrogens as well as the duration of clinical signs.25 
Physical examination should include examination of both mammary chains and evaluation of the health 
condition of the patient,14 aiming to determine the number of affected glands, the tumour size, texture 
and location, evidence of tumour ulceration and fixation to underlying tissues and evidence of distant 
metastases.25,26 Generally, palpation of subcutaneous nodule(s) or mass(es) within one or many glands 
simultaneously is highly suggestive of MTs.27 When evaluating a cat with a prior history of mammary 
tumours, especially if treated with simple mastectomy, a careful examination of the remaining mammary 
glands is mandatory, because new primary tumours are common.15  Nodules may be discrete, well 
defined, firm or mobile and attached to skin or underlying tissues (Figures 2 and 3).  A few nodules may  
 
Figure 1- The four pairs of mammary glands in the cat, with their associated lymph nodes and lymphatic 
drainage. Adapted from dkhaines, 2009, The University of Tennessee 
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appear cystic, inflamed, infected and ulcerated mainly if associated to an extensive tumoural 
necrosis.7,8,15,27  
In general, nodules are located in adjacent ipsilateral glands and are often considered to be caused by 
lymphogenous spread of a single primary tumour. Contralateral concomitant neoplastic nodules are 
observed less frequently and may be associated with haematogenous involvement.27 In fact, until 
recently, it was thought that spread into contralateral mammary glands occurred through lymphatic 
vessels but no interglandular lymphatic connections were identified.23 Recent studies reported that 
metastization to contralateral glands probably occur through venous system that is shared by the 
glands.16 
In case of inflammatory mammary carcinomas, the glands may be swollen, hot and painful, with 
extensive lymphatic involvement. This presentation may be difficult to differentiate from 
fibroadenomatous hyperplasia (fibroepithelial hypertrophy, feline mammary hypertrophy) (Figure 4), 
although the latter is more common in young cats8,15 and is usually characterized by a more typical 
presentation with one or multiple enlarged mammary glands and without milk production.16 In a case of 
feline primary inflammatory carcinoma reported by Millanta et al. (2012), this was characterized with 
rapid onset of oedema, severe erythema, local pain and warmth of the inguinal region, with a pustular-
to-nodular cutaneous lesion in association with an ill-defined underlying mass.28 
Perez-Alenza et al. (2004) has described the same characteristics (rapid onset of erythema, severe 
oedema, extreme local pain and firmness, absence of subjacent mammary nodules, and involvement 
of extremities) in three cases after surgical excision of a malignant mammary tumour, and they were 
classified as secondary postsurgical inflammatory mammary carcinoma.29 
 
 
 
 
 
Figure 2 – Subcutaneous nodules in mammary gland. (Kindly 
provided by Dr. Hugo Vilhena, Hospital Veterinário do Baixo 
Vouga) 
Figure 3 - Subcutaneous nodules in mammary gland. 
(Kindly provided by Dr. Hugo Vilhena, Hospital 
Veterinário do Baixo Vouga) 
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Some nonspecific clinical signs may appear such as weight loss, inappetence and lethargy, and less 
commonly, exercise intolerance. Mammary tumours have a high metastatic potential not only to  the 
regional lymph nodes but also into lungs, pleura, liver, skeleton, spleen, kidneys and to distant lymph 
nodes.27 In cats, pulmonary metastases are more frequent than regional metastases.7,8,14,30   
Respiratory distress (dyspnea or cyanosis) and pleural effusion caused by diffuse pulmonary 
metastases is common due to pleural carcinomatosis and extensive pulmonary involvement. 25,27,31,32  
Due to distant metastization, the sternal, inguinal and axillary lymph nodes should be examined for size, 
consistency and, if suspicious, should be analysed by fine needle aspirate (FNA) or biopsy for detection 
of tumour infiltration. Paraneoplastic syndromes are uncommon.7,8,12,14,15 
In addition to the collection of a detailed history and to the physical examination the diagnosis of MTs 
should also include a complete blood count, serum biochemistry, urinalysis, determination of serum 
tiroxine (T4) concentration and Feline Immunodeficiency Virus/Feline Leukaemia Virus infection 
status.14,15,30 A coagulation profile is indicated if an inflammatory mammary carcinoma is suspected, due 
to the high association with disseminated intravascular coagulation.33 
To evaluate the presence of distant metastases, three-view thoracic radiographs (including ventrodorsal 
and right and lateral views, preferably performed under anaesthesia with inflated lungs) and abdominal 
ultrasonography should be performed.8,16 Pulmonary metastases may appear as a small to large nodular 
opacities on thoracic radiographs.7,8,14,30 Advanced imaging computed tomography, when available, 
should also be performed since it provides more accurate assessment of lung metastases clarifying 
doubts on the radiographic exams.8 
As previously reported, FNA of lymph nodes as well as scraping of ulcerated lesion and  cytology of 
fluids from affected glands or pleural effusion should also be performed to rule out skin and 
subcutaneous non mammary malignancies and/or to differentiate mammary carcinoma from 
fibroadenomatous hyperplasia.16  Particular attention should be given to the cytologic examination since 
it may yield false negative results.25,30 Cytology could be essential to differentiate tumours from 
inflammatory processes, but the distinction between benign and malignant MTs may be difficult. 
Therefore, if cytology do not allow a definitive diagnosis, excisional biopsy with subsequent 
Figure 4 – Fibroadenomatous hyperplasia (Kindly provided by Dr. Hugo Vilhena, Hospital Veterinário do Baixo 
Vouga 
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histopathologic examination is recommended in order to determine the malignancy of the tumour prior 
to define the adequate treatment.8,16 Histopathologic examination of the excisional biopsy is considered 
the gold standard for the diagnosis of feline MTs.12,27 
 
3. HISTOPATHOLOGY AND BIOLOGICAL BEHAVIOUR OF MAMMARY TUMOURS  
 
Tumours of the mammary gland of felines are histologically classified according to the diagnostic criteria 
proposed by the World Health Organization (WHO) as summarized in Table 1.34 These tumours are 
mainly classified based on descriptive morphology and divided into four main groups: mammary 
hyperplasia/dysplasia; benign tumours, malignant tumours, and unclassified tumours.14,27,34 
 
3.1 Hyperplasia and Dysplasia 
Fibroadenomatous change (fibroepithelial hyperplasia, fibroepithelial hypertrophy, mammary 
hypertrophy) is characterized by a rapid and abnormal proliferation of interlobular ducts and periductal 
stromal cells of one or more mammary glands, table 1.15,16 This alteration is more commonly detected 
in the cat than in the dog.15,16 
 
3.2 Benign mammary tumours 
Benign fibroadenoma is the most frequently reported benign mammary tumour in cats, with simple 
adenoma or duct papilloma rarely seen, table 1.15  
 
3.3 Malignant mammary tumours 
There are some criteria that help to differentiate adenocarcinomas from benign MTs, such as atipia in 
the epithelial component of the tumour growth, infiltrative growth, high mitotic activity and cellularity, 
and/or necrosis.12  
The most frequent histological type of malignant tumour is the simple adenocarcinoma. This carcinoma 
is derived from the luminal epithelium of the mammary ducts and alveoli. Other types of malignant 
mammary tumours are very rare in queens, namely squamous cell carcinoma, mucinous carcinoma and 
carcinosarcomas, table 1.8,14,34  
Complex carcinoma (biphasic epithelial myoepithelial) is a different and unusual histological type in 
queens that was described by Seixas et al. (2007). This type of carcinoma shows histopathological 
features distinctive from other tumours, being characterized by the presence of two cell populations, 
epithelial luminal cells and mioepithelial cells.35 These tumours have low grade of malignancy and it 
appears to have a better prognosis and disease-free-survival rates than other carcinomas on 
queens.35,36 In addition to these carcinomas it was also reported in a cat, a very rare type of carcinoma, 
a lipid-rich carcinoma of the mammary gland, which seems to be a variant of mammary carcinoma in 
cats.37  
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Mammary 
Hyperplasias/Dysplasias 
Ductal hyperplasia 
 Lobular hyperplasia 
 Epithelial hyperplasia 
 Adenosis 
 
Fibroadenomatous change (feline mammary hypertrophy, 
fibroepithelial hypertrophy) 
 Cysts 
 Duct ectasia 
 Focal fibrosis 
  
Benign tumours Adenoma 
 Simple Adenoma 
 Complex Adenoma 
 Fibroadenoma 
 Low-cellularity fibroadenoma 
 High-cellularity fibroadenoma 
 Benign mixed tumour 
 Duct papilloma 
  
Malignant Tumours 
 
Noninflitration (in situ) carcinoma 
 Tubulopapillary carcinoma 
 
 
Solid carcinoma 
Cribriform carcinoma 
 Squamous cell carcinoma 
 Mucinous carcinoma 
 Carcinosarcoma 
 Carcinoma or sarcoma in benign tumour 
  
Unclassified Tumours  
Table 1- Histological Classification of Mammary Tumours of the cat, defined by WHO. 
Adapted from Misdorp, 1999. 
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4. HISTOLOGICAL GRADING SYSTEM 
 
The histological grading of the feline MT is adapted from the human grading systems and takes into 
account several morphological criteria.38,39 In a large number of studies, the histological grade is 
determined according to an adaptation of the classification used by Elston and Ellis. This, histological 
grading system is based on the degree of tubule formation, degree of nuclear and cellular pleomorphism, 
and mitoses activity.12,13,19, 39,40 The histological grade is defined by the sum of individual scores for these 
features and a score of 1 to 3 is given for each, as it is described on table 2.12,38 
 
Table 2- Individual scores for assessing histological grade in feline mammary carcinoma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
For degree of tubular formation, a score of one point is given when more than 75% of the examined 
area exhibited definite tubular formation; two points are for tumours in which the tubules occupy about 
10 to 75% of the area; and three points are when the tubules occupy 10% or less of the area.38,41 
Nuclear pleomorphism is scored qualitatively. One point is given when nuclei are small, with minimal 
increase or with variation in size, regular outlines and uniform chromatin; when nuclei is larger than 
normal with vesicular nuclei and single visible nucleoli, and moderate variation in shape and size is 
scored two points; for marked variation in size and shape, with very large, bizarre, and vesicular nuclei 
with prominent and multiple nucleoli is given three points.38,41 
Criteria Score 
Tubule Formation  
Majority of tumour (>75) 1 
Moderate degree (10-75%) 2 
Little or none (<10%) 3 
Nuclear pleomorphism  
Small, regular uniform cells 1 
Moderate increase in size and variability 2 
Marked variation 3 
Mitotic counts  
Dependent on microscope field area 1-3 
Adapted from Elston and Ellis, 1998. 
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Regarding, mitotic count, this is evaluate quantitatively and the count of this feature depends on 
microscope field area.38,41 
The overall tumour grade results from the sum of the individual scores. For a sum between three to five 
points the tumour is considered a well-differentiated carcinoma (grade I); for a sum between six and 
seven points the tumour is considered a moderately differentiated carcinoma (grade II); and the sum is 
between eight and nine points the tumour is considered a poorly differentiated carcinoma (grade III).38,41 
Recently, it was evaluated the possible correlation between the histological grade, using the Elston and 
Ellis method, and the post-surgery survival of queens with mammary carcinomas. The results 
demonstrated that tumour grade using this method way be considered an independent prognostic 
factor.42 
According to this study, the histological grading system is a good parameter to stratify tumour according 
to their morphological characteristics and aggressive biological behaviour, in order to establish a 
correlation between the morphological structure of tumours and their clinical behaviour.12,42 Histological 
grade may also provide useful information to predict the response to chemotherapy and, therefore, be 
a predictive factor.42 
 
5. STAGING 
 
In order to plan the adequate therapeutic approach and prognosis, it is essential to determine the local 
extent and the degree of spread throughout the body.8,16   
The WHO’s TNM (tumour-node-metastases) classification system is usually applied to staging tumours 
in domestic animals and takes in consideration criteria related with the size of the  primary tumour, the 
presence of lymph node and distant visceral metastases.8,16,27 A modified WHO clinical staging system 
established from the original system published by Owens is applied to the feline mammary tumours, 
except to the mammary gland sarcomas.15,43  
The extent of the primary tumour (size and clinical evidence of local invasion, such as fixation to skin or 
fascia) is represented by “T”.16,43  As the size of the tumour is important to the prognosis, it should be 
measured with callipers: those 3 cm diameter are associated with better survival rates than those >3 
cm.8,43 The “N” is associated to the presence of tumour cells at the regional lymph nodes. Normal-sized 
lymph nodes may still contain tumour cells, thus, the regional lymph nodes (axillary and inguinal) should 
be examined and FNA or surgical removal may be necessary to help categorize N status.16 The “M” 
designates the presence or absence of distant metastases.8,16 By using these criteria, tumours are 
classified in stage I to IV, as summarized on table 3 and 4.16 
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Table 3- TNM Classification system for mammary tumours of domestic animals 
 
 
 
Table 4- Staging of Feline Mammary Tumours 
 
Stage T Classification N Classification M Classification 
I T1 N0 M0 
II T2 N0 M0 
III T1, T2 N1 M0 
 T3 Any N M0 
IV Any T Any N M1 
 
 
6. MOLECULAR CHARACTERIZATION 
 
The molecular characterization of mammary tumours represents a new stage in the development of 
effective predictive models and targeted therapies.44,45,46 A molecular marker could be deoxyribonucleic 
acid (DNA) or ribonucleic acid (RNA) based or a protein directly measured in tissues, serum, or other 
organic fluids that can be used for tumour detection, tumour staging, monitoring of response to therapy, 
and prediction of patient prognosis.47 Considering that tumour cells are characterized by increased 
proliferation rate, resistance to death, increased ability to invade surround and distant tissues and 
increased ability to promote angiogenesis, the search for markers is orientated to signalling pathways 
that control these characteristics.44,45 In cats, there are several molecules that are being investigated in 
order to understand their role in the development of MTs, such as oestrogen receptors (ER), human 
epidermal growth factor receptor-2 (c-erbB-2/HER2/neu), and the vascular endothelial growth factor 
(VEGF).24, 48 Others molecules such as cadherins, integrins, p53, topoisomerase IIβ binding protein 1 
(TopBP1), PI3K/AKT, phosphatase and tensin homolog (PTEN), c-kit are also under 
Tumour size 
(diameter) 
(T) 
Classification 
Regional 
Lymph nodes 
Metastases (N) 
Classification 
Distant 
Metastases 
(M) 
Classification 
<2cm T1 
Without 
metastases 
N0 
Without 
metastases 
M0 
2-3cm T2 
With 
metastases 
N1 
With 
metastases 
M1 
>3cm T3     
Adapted from Owen, 1980. 
Adapted from Owen, 1980 
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investigation.40,49,50,51,52 However, until now there are no consistent results regarding their contribution 
to the tumorigenesis and there are no studies regarding their utility as prognostic markers. Additional 
studies are needed to clarify the role of these molecules in feline MTs.8          
 
7. TREATMENT 
 
Treatment options depend on tumour staging and can include surgery, radiation therapy, chemotherapy, 
or a combination of treatments. Palliative care is also important in oncologic patient especially in tumours 
that at the moment of diagnosis already present metastases, such as, what frequently occurs in the 
malignant MT.8,15 
 
7.1 Surgery  
Surgical excision of MTs remains the most widely accepted treatment option for feline MTs, however it 
is usually not curative due to the ability of these tumours to invade surround and distant tissues.16,27  
Complete removal of neoplastic tissue is hampered by the degree of invasion and ulceration.16 Due to 
the invasive nature of malignant MT and to the tendency of these tumours to early metastases, the 
treatment of choice for tumours without signs of distant metastases is radical mastectomy of the affected 
side, regardless of tumour size.53 After surgery, the entire specimen with the surgical margins inked 
should be submitted for histological review to ensure that complete margins have been obtained.16 
Malignant mammary neoplasms in the cat often invade lymphatics and veins. The lymphatic drainage 
in mammary gland of queen influences the extent of surgery, as tumour cells spread readily beyond the 
primary site.8 Therefore, the recommended approach based on drainage studies is to perform chain 
mastectomy with removal of draining lymph nodes: unilateral mastectomy if the tumour is confined to 
one side, or a two staged bilateral chain mastectomy (with a two week interval between surgeries) for 
cats with bilateral tumours.8,15,16 According previous studies, the extent of surgery could influence the 
development of local recurrence as well as the disease-free interval (DFI) and the survival time 
(ST).8,54,55 Taking into the account the invasion of veins, early vessel ligation is essential, when 
performing radical unilateral or bilateral chain mastectomy.16 
In addition to the removal of the draining lymph nodes, the inguinal lymph node is always removed with 
the A2 (Figure 1), whereas the axillary lymph node is removed, only if it is enlarged or if it is positive for 
tumour spread on FNA or biopsy.8,16 Prophylactic removal of axillary lymph nodes is unlikely to have a 
therapeutic benefit and extends survival.8,16 
Tumour fixation to skin, muscular fascia or portions of the body wall should be included with en bloc 
resections.15,16  
The question of perform OHE at the same time of radical mastectomy, has been long discussed.27,56 
There is no evidence that OHE has any benefit in prevention of the development of metastases 56, 
neither on survival or tumour recurrence and has no effect on development of new tumours in the 
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remaining mammary glands or tumour progression.8 However, OHE may be beneficial in order to reduce  
the use of progestin therapy.8 
 
7.2 Chemotherapy 
Early detection and aggressive surgery can result in long-term survival in cats with early stage MTs, 
however because of the high rate of metastases after surgery, adjuvant chemotherapy is commonly 
recommended for the treatment of feline mammary carcinomas.3,15 The benefit of using chemotherapy 
as an adjuvant therapy to surgical excision is still not clear 8, but cats with delayed diagnosis, large 
primary tumours, metastatic local lymph nodes or  vascular or lymphatic invasion are usually submitted 
to adjuvant chemotherapy in order to reduce the occurrence of recurrences and the development of the 
metastases.15, 33 In addition, the systemic adjuvant chemotherapy may be useful, for providing pain relief 
in cats with unresectable tumours.7 Some antineoplastic drugs are used, alone or in combination, as 
adjuvant therapy in malignant MTs, namely doxorubicin, carboplatin, cyclophosphamide, vincristine, 
methotrexate and mitoxantrone.7,27,30 
Doxorubicin is considered one of the most active agents for patients with advanced disease and 
chemotherapy protocols commonly used for feline mammary carcinoma include doxorubicin as a single 
agent or in combination with cyclophosphamide.3,33 In a large retrospective multicentre study performed 
in 2006 with 67 cats, mammary adenocarcinomas, received adjunctive single-agent doxorubicin at a 
dose of 1 mg/kg intravenously every three weeks for a maximum of five treatments, or until the cat 
develop progressive disease or concurrent illness. The results from this study showed that cats that 
completed the protocol had significantly improved survival with a median survival time (MST) of 448 
days and a DFI of 255 days.57  Similar results were obtained by Borrego et al. (2009) who also evaluated 
the efficacy of treatment with a Cyclooxygenase – 2 (COX-2) inhibitor (meloxicam), a doxorubicin-based 
chemotherapy protocol and surgery in 23 cats with mammary adenocarcinomas. In the study of Borrego 
et al., which did not have a control group it reported a MSTs of 460 days and DFI of 269 days.58  
The effect of adjuvant doxorubicin-based chemotherapy in the outcome of feline mammary carcinoma 
compared with surgery alone has been also accessed, in study of McNeill et al. (2009).3 Adjunctive 
chemotherapy was defined as chemotherapy treatment after definitive surgery to remove the primary 
tumour and before any recurrence or progression.3  Seventy-three cats were evaluated, of which 37 
were only submitted to surgery (MST=1406 days; DFI=372 days) and 36 were submitted to surgery and 
then to chemotherapy group (MST=848 days; DFI=676 days). In the spite of the differences, the 
statistical analysis of the MST and DFI obtained in both groups did not identify an overall benefit of 
adjuvant chemotherapy.3 There were no significant differences in clinical data (surgical procedures, 
tumour size, stage, or histopathologic parameters).3 
The combination of doxorubicin with cyclophosphamide may shrink tumour in 35 to 50% on cats with 
unresectable locally disease or distant metastatic disease, with complete remission in 21% of patients, 
and thus increase ST.8,25,27,33 In addition, cats that responded to this combination therapy had a longer 
MST (150 to 180 days) than did those patients unresponsive to therapy (75 to 86 days).58,59 The 
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relatively high response rate in the macroscopic setting suggests that this may be an effective protocol 
in patients with microscopic minimal residual disease (i.e., following surgical cytoreduction). However, 
results from adjuvant studies do not reflect this, albeit none of the studies were prospective or 
randomized.15 
Despite the apparent efficacy, chemotherapy has several side effects that should be considered. 
Treatment based on doxorubicin protocol can cause transient gastrointestinal side effects and other 
adverse complications such as anorexia, nephrotoxicity and myelosuppression.25,27,58,60 Furthermore, it 
is also important to evaluate the toxic effect of the chemotherapeutic drugs among liver and kidneys. 
Cyclophosphamide is activated by the liver and excreted by the kidneys, whereas doxorubicin is 
metabolised by the liver with only 5% excreted in urine. Therefore, the hepatic and renal functions 
should be assessed before using any of the protocols.14  
In summary, given the high metastatic potential of feline mammary carcinomas, the adjuvant use of 
systemic chemotherapy after radical mastectomy to maximize survival, could be considered upon the 
evaluation of the hepatic and renal function.25 Nevertheless, more studies are needed to clarify the 
actual effect of doxorubicin as well as to identify the malignant MTs that are more sensitive to 
doxorubicin.  
Alternatively, a different approach with anti-angiogenic metronomic (low dose) chemotherapy could be 
considered, although low dose chemotherapy using vincristine, cyclophosphamide and methotrexate 
was reported not to prevent recurrence or metastases.8 
 
7.3 Immunotherapy  
This is a method of cancer treatment that requires administration of immunomodulators to stimulate the 
host immune response to neoplastic cells.16 
The immunomodulators like bacillus Calmette-Guerin (BCG), Corynebacterium parvum, liposome-
encapsulated muramyl tripeptide phosphatidylethanolamine (LMTP-PE) and levamisole have been used 
as adjuvants to surgical excision of feline mammary tumours.54,55,61 
The administration of Corynebacterium parvum vaccine, either intratumorously or subcutaneously, in 
combination with surgery was been showed not to be successful.55  In addition, the LMTP-PE used to 
stimulate monocyte cytotoxic activity following radical mastectomy also did not improve the DFI or ST 
of cats when compared with placebo-treated cats.54 McEwen et al. (1984) reported that treatment of 
feline malignant MTS with oral levamisole (5mg/kg, 3 days a week) as an adjuvant to surgery was 
ineffective in altering the recurrence rate of disease and did not increase the ST of treated cats compared 
with control groups.61 
The small molecule inhibitors that target receptor tyrosine kinases (receptor tyrosine kinase inhibitors or 
RTKIs) are effective in the management of some types of veterinary cancers, particularly those with 
altered tyrosine kinase activity. Imatinib and masitinib are well tolerated in cats; however, there is no 
information about their efficacy against feline mammary tumours.8 
 
 
14 
 
Santana et al. (2014) reported a case of a cat with a highly malignant MT treated with radical mastectomy 
and toceranib phosphate (3.33 mg/kg every 72 hours) and metronomic adjunctive chemotherapy  with 
cyclophosphamide (10mg/m2 every 48 hours).62 This was considered a good option to treat a feline 
patient after surgery.62 
 
7.4 Radiotherapy 
Radiotherapy is a local treatment used to prevent recurrences.30 However, there is no evidence that 
radiotherapy is beneficial in improving clinical outcome in feline MTs compared with surgery alone and 
is seldom used in the treatment due to lack of evidence to support increased survival rates in this 
species.7,16 
 
7.5 Hormonal therapy 
Endocrine therapy, namely tamoxifen, is widely used to treat oestrogen-receptor positive breast tumours 
in humans, but there are no reports of using anti-oestrogens in cats, probably because most malignant 
feline MTs lack oestrogen receptors and expected benefits would, therefore, appear to be minimal.8,27 
 
7.6 Supportive care 
Analgesia is essential during and after surgical removal of any MTs.30,63 Analgesics should be 
considered for patients suffering from large or ulcerated tumours, or painful metastases, such as to 
bone metastases. Nonsteroidal anti-inflammatory drugs (NSAID) and opioids may be beneficial for the 
supportive management of these advanced-stage patients.25 
Anti-emetics can be helpful at reducing the adverse effects of chemotherapy, and supplemental feeding 
methods and appetite stimulants must be considered in all patients to facilitate healing and prevent 
weight loss during therapy.30,63  
In addition, treatment of underlying secondary problems such as renal or heart disease is important.63 
 
8. PROGNOSTIC FACTORS 
 
One of the most important prognostic factors in cats with mammary gland neoplasia is tumour size or 
volume, which is associated to an increased risk for metastases and a reduced of both DFI and ST.16,39 
Furthermore, tumour size is an important  factor to determine  the need for adjuvant treatments.15,27  
Tumour size correlates with number of tumour cell divisions and higher chance for the progression to a 
more malignant behaviour due to accumulation of mutations.39 Three size categories have shown 
prognostic significance at initial presentation: (1) tumours smaller than 8 cm3 or smaller than 2 cm 
diameter; (2) tumours larger than 8 to 27 cm3 or larger than 2 to 3 cm diameter; and (3) tumours larger 
than 27 cm3 or larger than 3 cm diameter.8  
Tumour size appears to have higher prognostic relevance in mammary carcinomas larger than 3 cm in 
diameter.64 In fact, cats with tumours larger than 3 cm have a poor prognosis with a short ST (4–12 
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months). Cats with smaller tumours (<2 cm) can be effectively treated with surgery alone, with a mean 
ST higher than 3 years.8,15,64,65 On the other hand, cats with tumours of 2 to 3 cm in diameter had a 
mean ST of 2 years.15 Given this association between tumour size and ST, early diagnosis and treatment 
have an important bearing on the prognosis for cats with malignant MTs.16 
Another prognostic factor is the degree of dissemination at initial presentation. The presence of regional 
lymph nodes and pulmonary metastases at the moment of the diagnostic are associated with a worst 
prognosis.8,25,65  
In addition to the existence of metastases, the location of the metastases is also a prognostic factor.9,25 
In fact, Novosad et al. (2006) showed that in cats with metastatic disease in regional lymph node, lungs 
and pleura have  a MST of 1543, 332, and 188 days, respectively.57  
Another factor that is important to evaluate prognostic is the surgical technique. Radical mastectomy 
had a significantly reduced rate of local recurrence and produced a significantly longer DFI than 
conservative surgery.8,16 Weijer et al. (1983) reported that cats treated by mastectomy had a better 
prognosis than that cats treated by block dissection, because block-dissected cats showed more 
regional lymph node involvement.66  
Relatively to breed, a recent retrospective study showed that Siamese cats have a statistically worse 
prognosis with decreased median DFI and MST compared with Domestic shorthair cats.58,61  
Older cats have a worse prognosis,15 however, a prospective randomized trial found no difference 
according to age when comparing cats that were younger or older than 10 years.61 
As previously referred tumour size and lymph node involvement together with metastases at distant 
sites are used to stage MTs and to give a significant prognostic indication (TNM staging).27 In addition, 
clinical stage at presentation of feline mammary carcinomas and some of their anaplastic features have 
been reported to be useful prognostic indicators and has been shown to be associated with survival 
time.64 Median survival time of cats with stage I, II, III and IV were 29, 12.5, 9 and 1 month(s), 
respectively.67  
Histological subtypes of breast cancer have been described as prognostic in humans.34 However, Weijer 
et al. (1983), showed that in cats, the histologic type has not been found to be related to prognosis.66  
On the other hand, Novosad et al. (2006) reports that histological subtype is prognostic for DFI, with 
papillary or tubular, ductal, and anaplastic tumours having a DFI greater than 1131, 306, and 95 days, 
respectively.57 In addition, Castagnaro et al. (1998) reported that histologic grade was inversely 
correlated with prognosis and ST.13 In its study it was reported that the rate of death, one year after 
surgery was 0% in cats with grade I, and 100% in those with grade III.13 Yet, there was not a good 
correlation between moderated differentiation and ST.16 
The number of mitotic figures found in tumour tissue is an independent prognostic indicator.44 It 
correlates with ST and is significantly different between feline mammary carcinomas with various 
histological stage of invasion.44 Longer ST were seen in animals with tumour exhibiting fewer than two 
mitotic figures per high power field.66 
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Other markers of cell proliferation, including Ki-67, proliferating cell nuclear antigen (PCNA) and 
argyrophilic nucleolar organizer regions (AgNORs) have been used to determine high histological grade 
in feline MTs, and have been evaluated individually, but they have not been shown to be independent 
prognostic markers.8,25,44  
Ki-67 antigen is a non-histone nuclear protein expressed at various levels during the different phases of 
the cell cycle. Therefore the relative number of Ki-67 positive cells indicates the growth fraction.44,68  Ki-
67 generally measured on paraffin sections by immunohistochemical.44 The staining is higher in 
mammary carcinomas than in benign lesions, and has also been correlated with histological grade of 
feline mammary carcinomas, with higher grade tumours exhibiting more positive cells.44 It was 
suggested that Ki-67 was correlated with the post-surgical ST, but controversial results have been 
described for this index , table 5.44,68 
Proliferating cell nuclear antigen is an auxiliary subunit of DNA polymerase delta and is involved in DNA 
repair.44 Expression is maximal during the G1/S phase of the cell cycle.44 PCNA in feline mammary 
carcinoma has significant related to malignant tumours, reflecting greater mitotic activity, but has no 
correlation with degree of nuclear pleomorphism.25,27,44 Preziosi et al. (1995) reported that the PCNA 
value is correlated with mitotic index in mammary carcinomas when typical and atypical mitotic figures 
are considered together, table 5.69 
Argyrophilic nucleolar organiser regions are structural and functional nucleolar components associated 
with argyrophilic proteins involved in ribosomal ribonucleic acid transcription and processing.44 The 
AgNOR size and number might correlate with cell proliferation, for that reason some studies have 
evaluated its role in the malignant MTs.44 However the results obtained were controversial44,70,71 with  
no correlation between AgNOR size and tumour morphological sub-type, tumour stage, nuclear atipia, 
or mitotic index 72, whereas, other study relate AgNOR index to survival in univariate analysis and has 
an independent prognostic value in multiparametric survival test , table 5.70 
Metallothioneins are metal binding proteins which also have a role in proliferation, and apoptosis.44 In 
queens, immunohistochemical metallothionein was detected only in mammary carcinomas and no 
positivity in benign lesions and cases of fibroadenomatous hyperplasia.73 However, its role in feline MTs 
needs further investigation , table 5.73 
Other factors associated with malignant transformation and clinical outcome have been evaluated, 
including various molecular markers.25 The vascular endothelial growth factor is an angiogenic factor 
involved in new blood vessel formation and tumour microvessel density  and is routinely used to assess 
neoplastic angiogenesis.25 Tumour progression is usually associated with hypoxia which induces the 
production of nitric oxide, with subsequent stabilization of the hypoxia inducible factor-1-α (HIF-1-α), that 
in turn stimulates the production of the pro-angiogenic VEGF.74, 75 In human breast cancer, retrospective 
studies suggest that VEGF plays a relevant biological role in their progression also that high levels of 
VEGF is associated to poor prognosis, and who may benefit from validated anti-VEGF treatments.76 In 
feline mammary carcinomas, studies performed by Millanta et al. (2006) indicated that an increased 
 
 
17 
 
VEGF expression is correlated to tumour anaplasia and shorter overall survival time, indicating that 
VEGF could be considered a prognostic indicator in feline MTs, table 5.16,25,41,44,77 
Considering that the development of a tumour is usually associated to an increased production of nitric 
oxide, that together with HIF-1-α stimulate the production of VEGF, several studies determined  the 
expression of nitric oxide synthase (NOS) isoforms, like the endothelial and inducible NOS (e/iNOS) 
and VEGF in feline MTs in order to clarify the correlations between these proteins and their relationship 
with angiogenesis and microvessel density.74 iNOS immunoreactivity was localised in tumour cells and 
sporadically in stromal myofibroblasts, whereas eNOS and VEGF were localised in the cytoplasm of 
tumour epithelial cells and endothelium. Expression of iNOS was increased in malignant tumours and 
was significantly higher in grade III and grade II when compared with grade I cases.74 Furthermore, 
expression of iNOS was positively correlated with VEGF and microvessel density of feline MTs and both 
measures were significantly greater in less differentiated phenotypes. However, increasing eNOS 
expression was limited to hyperplastic lesions and showed no significant with histological grade.74 With 
this study was possible to conclude that the expression of NOS isoforms depends on tumour grade and 
positive correlations between iNOS and angiogenic markers suggests that iNOS synthesised by tumour 
cells promotes tumour growth, table 5.74 
In human breast cancer, mutations in the tumour suppressor gene p53 confer a worse prognosis 
independently of other risk factors.44 To evaluate the role of p53 in feline MTs it was performed a study, 
that showed that 17,3 % of feline mammary carcinoma express this protein, while there was no p53 
expression in benign lesions.27 Other study, reported that the expression of p53 vary from 18.9% to 33% 
in feline carcinomas, and there was no expression in adenosis and fibroadenoma.44 However, until now 
there is no persuasive evidence that assessment of p53 expression by immunohistochemistry holds 
great prognostic potential for feline MTs , table 5.44 
Another molecule that has been studied in feline MTs is COX-2. Millanta et al. (2006), found COX-2 
expression in 96% of the feline MTs and associated this with a poor prognosis, table 5. However, Beam 
et al. (2003) reported the absence of COX-2 expression in all adenocarcinomas of  feline mammary 
gland, table 5.78,79 In addition, Sayasith, et al. (2009), showed that a large proportion (87%) of feline 
MTs expressed COX-2 and this has also been linked to poor prognosis, table 5.80 However these results 
from Sayasith, et al. (2009) were complicated by the fact that it also correlates with expression of the 
angiogenic factor VEGF, which itself is significantly correlated with overall survival, table 5.80 The COX-
2 expression, also has been correlated with negativity for oestrogen receptors (ER) and increased 
expression of progesterone receptors (PR).24 
In order to understand the role of steroid hormones in MTs tumorigenesis, the expression of oestrogen 
receptors α (ERα) and PR were studied by immunohistochemistry and biochemical methods.24,48,81,82,83 
The results demonstrated that in the in situ carcinomas the expression of ERα and of PR varies between 
7% and 17% respectively, while in invasive carcinomas the expression of ERα and of PR ranges from 
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15% to 40%, respectively.48,81 Some studies pointed progesterone as the main contributor to 
tumorigenesis, since expression of PR in malignant tumours is significantly higher than the expression 
of ERα.24,48,81 Moreover, several studies reported a statistically significant decrease in ER positivity in 
invasive carcinomas when compared with normal and dysplastic tissues48,81,82, and in the study 
performed by Maniscalco et al. (2013), there was a positive correlation between ERα expression and 
benign neoplasia.84 Due to these results, it was suggested that MTs loose steroid dependence during 
malignant progression.48,82 
In contrast, a statistically significant increase in the PR expression was reported in neoplastic lesions 
when compared with healthy and dysplastic tissues.48 In a study performed by Millanta et al. 2006, the 
PR expression reached the maximum expression in the in situ carcinomas, and a progressive decrease 
in invasive tumours; nonetheless, 61,7% of the samples were still PR positive. Therefore, it is considered 
that oestrogen exposure may constitute a risk for the development of tumours, but the expression of ER 
and of PR in invasive carcinomas do not correlate with histological parameters or with overall ST.24 
The human epidermal growth factor receptor-2 is one of the best characterized breast cancer marker in 
human medicine.85,86 This receptor is composed by an intracellular tyrosine kinase domain and once 
activated through a set of ligands (endothelial growth factor or transforming growth factor-α)  will activate 
downstream signal transduction pathways that control cell growth, regulate cell survival and apoptosis 
through the Ras/Raf/mitogen-activated protein kinase pathway, the PI3K/AKT pathway, protein kinase 
C (PKC) among others.87 The overexpression of HER-2 is caused by the amplification of the HER-2/neu 
proto-oncogene.88,89 In humans, it has been demonstrated that gene amplification and/or 
overexpression of the c-erbB-2/HER2/neu tyrosine kinase is associated with poor prognosis 
in breast cancer, , table 5.89,90  
In cats, the role of c-erbB-2/HER2/neu in MTs is controversial since the results vary significantly. 
According to Rasotto the incidence of c-erbB-2/HER2/neu overexpression in  feline MTs is of 5,5%.91 
However, in a study performed by Maniscalco et al. (2013) the incidence of c-erbB-2/HER2/neu  
overexpression was 33,33%, in a study performed by Ordás et al. (2007) the incidence was 40%, and 
in a study performed by Millanta et al. (2005) the incidence was 59,6%, table 5.24,84,88,92 Besides the 
controversies, some studies consider that HER-2 overexpression did not show significant correlation 
with histologic type, tumour grading, or presence of lymphatic invasion, but its expression seems to 
correlate with shorter overall survival, table 5.84,88,91 
Topoisomerase IIβ binding protein 1 is a nuclear protein that has structural and functional similarities 
with gene BRCA2.93 In feline MTs, TopBP1 expression has been positively correlated with histological 
grade, and in high grade carcinomas there was convincing correlation with ERα negative status.44 The 
expression of TopBP1 in feline MTs increases with increasing grade of malignancy but until now there 
is not clear evidence that this molecule to use this molecule could be used as a prognostic marker, table 
5.93 
Another important molecule is the tyrosine kinase receptor gene (RON) which is involved in the 
activation of the signalling cascade responsible for invasive properties of neoplastic cells.94 The study 
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of the expression of RON stem cell-derived tyrosine kinase (STK) homologue gene in cats, showed that 
its expression is significantly increased in feline mammary carcinoma.95 In fact, RON/STK was found to 
be expressed at a very high level in 20% of feline mammary carcinomas, however further studies to 
evaluate its possible contribution as a prognostic marker are needed, table 5.95 
Cadherins are cell adhesion molecules important in the morphogenesis and maintenance of the normal 
tissue architecture.96 The reduction or absence of E-cadherin expression and abnormalities in the 
pattern of immunostaining were evidenced in a subgroup of feline mammary carcinoma but its role as 
a prognostic factor is not fully understood, table 5.97 
The AKT, also known as protein kinase B, is a serine/threonine protein kinase which, when activated by 
phosphorylation (p-AKT), promotes growth factor-mediated cell growth, proliferation, migration and 
survival.52 The expression of AKT was correlated with malignancy and tumour differentiation, and was 
associated with a shorter DFI but further studies are needed to better understand its role in feline MTs, 
table 5.52 
Phosphatase and tensin homolog belongs to the group of gatekeeper tumour suppressor genes and is 
involved in multiple mechanisms leading to cellular defence against neoplastic transformation and 
progression.51 In a recent study, loss of PTEN expression as revealed by immunohistochemistry was 
found in 76% of feline mammary carcinomas. Furthermore, the female cats with PTEN-negative tumours 
had a worse prognosis, and the loss of PTEN expression was significantly correlated with lymphatic 
vessels invasion on feline mammary carcinoma.51 In spite of these results larger studies are needed to 
clarify the importance of PTEN to the prognostic of MTs, table 5.51 
Cyclin A is a gene that regulates the cell cycle and it is commonly targeted in feline MTS.98,99 Over-
expression of this gene were found in mammary carcinoma.98,99 The results suggest that cyclin A may 
be associated with tumorigenesis in cases of feline mammary carcinomas but there is no information 
regarding its role as prognostic factor, table 5.98,99 
Another factor that can constitute a marker for diagnosis and also a marker of prognosis is the presence 
of cancer stem cells (CSC). It is generally accepted that CSCs are involved in the tumorigenesis process 
due to its self-renewal ability, differentiation potential and tumour-initiating ability. In an experimental 
study performed by Pang et al. 2013 it was demonstrated that CSC from feline mammary tumours 
contribute to invasiveness and resistance to radiation and chemotherapy, table 5.50 
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Table 5 – Molecular markers and their prognostic value  
Molecule Expression Prognostic value 
Ki-67 
Increased in malignant MT and higher 
grade 
Controversial results 
AgNOR Increased in malignant in MT Further investigations 
PCNA Increased in malignant MT Controversial results 
Metallothioneins Increased in malignant MT Further investigations 
VEGF Increased in malignant MT 
Shorter overall survival 
time 
iNOS 
Increased in malignant MT and Grade II 
and III 
Poor prognostic 
eNOS Increased in hyperplastic lesions Further investigations 
p53 Increased in malignant MT Poor prognostic 
COX-2 Malignant MT (96% - Millanta et al. (2006) Poor prognostic 
 
Malignant MT (87 % - Sayasith et al. 
(2009)) 
Poor prognostic 
 
Absence in Malignant MT (Beam et al. 
(2003)) 
 
HER-2/neu 
Malignant MT (5,5% - Rasotto et al. 
(2011)) 
Poor prognostic 
 
Malignant MT (33,3% - Maniscalco et al. 
(2013)) 
Short overall survival 
 Malignant MT (40%-  Ordás et al. (2007)) Short overall survival 
 
Malignant MT (59,6% -  Millanta et al. 
(2005)) 
Short overall survival 
TopBP1 Increased in high grade of malignant MT Further investigations 
RON Increased in malignant MT Further investigations 
E – Cadherin Reduction or absence in malignant MT Further investigations 
AKT Malignant MT and tumour differentiation 
Shorter DFI/ Further 
investigations 
PTEN Loss in malignant MT 
Poor prognosis/Further 
investigations 
Cyclin A Increased in malignant MT Further investigations 
Cancer Stem 
Cells 
Increased in malignant MT Poor prognosis 
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9. CONCLUSION 
 
Feline MTs comprise approximately 12% of the feline tumours. Approximately 85% to 95% of the MT 
are malignant and have a poor prognosis due to a high ability of proliferation, high probability of local 
and distant invasion at the time of diagnostic and due to the high recurrence ratio. 
In spite of the prevalence and aggressiveness of these tumours, its aetiology remains poorly understood. 
Some studies pointed several risk factors for MT namely age, breed, reproductive status and exposure 
to oestrogen and progesterone but the clear contribution of each one to the tumorigenesis of the MT is 
still poorly understood. 
Regarding tumour classification, most of the studies use the criteria proposed by the World Health 
Organization (WHO) which facilitates the interpretation of the results. The histological grade is 
considered a reliable prognostic parameters, however, there is a lack of uniformity among techniques 
used to obtain the tumour grade which introduce a bias in the interpretation of the results. 
The literature also evidence a clear lack of uniformity among the evaluation of the prognostic factors. 
Most of the studies are retrospective which difficult the accurate collection of information, do not use 
similar methodology in the design of the studies, use different inclusion criteria of the patients, most of 
them are non-randomized studies and include a reduced number of patients. Together, these variables 
turn difficult the comparison of the results and the establishment of an adequate conclusion regarding 
the role of each molecule. Due to these discrepancies is still difficult to establish a prognostic and also 
to understand the mechanisms involved in recurrences. 
 Furthermore, due to the lack of uniformity among studies it is difficult to understand the role of adjuvant 
chemotherapy in the feline MTs and therefore it is difficult to establish an adequate therapeutic strategy. 
The most recent studies are studying the molecular characterization of feline MTs which may represent 
a new stage in the characterization of the tumours and also in the development of effective targeted 
therapies. These studies may contribute to the understanding of the aggressiveness of the MTs and 
therefore to the establishment of individual therapeutic strategies, opening a new era in the study of the 
feline MTs. 
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